Back Cami Morell, Jordi

CAMI MORELL, JORDI

JORDI CAMI MORELL
Departament de Ciències Experimentals i de la Salut
Coordinator of Science in Action

Jordi Camí MD, PhD, is Professor of Pharmacology (specialist in Clinical Pharmacology) at Pompeu Fabra University, General Director of the Barcelona Biomedical Research Park (PRBB), and Director of the Pasqual Maragall Foundation.

Between 1985 and 2005, he was the Director of the Municipal Institute of Medical Research in Barcelona (IMIM).

His academic activity has been developed between the Autonomous University of Barcelona (UAB) and the Pompeu Fabra University (UPF), holding different positions in both universities.

Between 1997 and 2002 he was responsible for the conception and development of the Health and Life Sciences studies at Pompeu Fabra University.

He also promoted the creation of new research centres as the Center for Genomic Regulation (CRG) or the Center of Regenerative Medicine in Barcelona (CMRB), and especially he led the creation of the Barcelona Biomedical Research Park (PRBB), that he leads since 2005.

He is author of more than 150 publications and several monographs related to Drug abuse, as well as he has directed 15 PhD theses.

He is also the author of the "Code of Good Scientific Practices" adopted since 2001 by all scientists belonging to the PRBB centres.

Research lines

His main research activity has been focused, for more than 25 years, in the neurosciences field, particularly in the clinical pharmacology of drug abuse.

He specialized in the evaluation of the effects of the simultaneous consumption of different drugs (alcohol, cocaine, THC) in humans, and the clinical and pharmacological effects of MDMA (ecstasy).

One of the first Detoxification Units for heroin addicts in Spain was created in 1981 at the Hospital del Mar of Barcelona under his responsibility.

In 1988 he was the founder member and first President of the Spanish Society of Drug Addictions (SET).

He currently focuses his research in the fields of Bibliometrics, Evaluation and Science Policy.